# OnCo record paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019" ;
  schema:name "POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer"@en ;
  schema:description "In patients with inherited BRCA mutations whose pancreatic cancer had been held in check by platinum chemotherapy, switching to the tablet olaparib roughly doubled the time before the disease grew again compared with placebo. It was the first biomarker-driven approval in pancreatic cancer."@en ;
  schema:url <https://onco.cc/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1903387>, <https://pubmed.ncbi.nlm.nih.gov/31157963/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1903387> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Golan T, Hammel P, Reni M, et al." ;
  onco:cancers <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/> ;
  onco:trials <https://onco.cc/trials/polo/> ;
  onco:people <https://onco.cc/people/talia-golan/> ;
  onco:journals <https://onco.cc/journals/nejm/> .